GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET FORECAST 2020-2028

  • You are here:
  • Home
  • Reports
  • GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET FORECAST 2020-2028

GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET FORECAST 2020-2028

The global Alzheimer’s disease therapeutics and diagnostics market is anticipated to grow at a CAGR of 5.21% between 2020 and 2028 and is anticipated to generate revenue of $15.16 billion million by 2028. Alzheimer’s disease is a progressive, degenerative ailment that attacks the brain’s neurons, ensuing in loss of thinking, memory, behavioral changes, and language skills. The important drivers increasing growth in the global Alzheimer’s disease therapeutics and diagnostics market are the growing geriatric population and the rise in the pervasiveness of Alzheimer’s disease. Alzheimer’s disease is the key reason for dementia among the old age population, which is a normal part of the general aging process. Therefore, the rising geriatric population globally acts as a key driver for the global Alzheimer’s disease therapeutics and diagnostics market.

GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET FORECAST 2020-2028

Global Alzheimer’s Disease Therapeutics and Diagnostics Market by Therapeutics and Diagnostics (Therapeutics(Therapeutics by Drugs, Therapeutics by Disease Stage, Therapeutics by Generic and Branded), Diagnostics) by Geography.

Request free sample

Report Summary

The global Alzheimer’s disease therapeutics and diagnostics market is anticipated to grow at a CAGR of 5.21% between 2020 and 2028 and is anticipated to generate revenue of $15.16 billion by 2028. Alzheimer’s disease is a progressive, degenerative ailment that attacks the brain’s neurons, ensuing in loss of thinking, memory, behavioral changes, and language skills.

The key factors boosting the global Alzheimer’s disease therapeutics and diagnostics market growth are:

  • Growing geriatric population
  • Growing pervasiveness of Alzheimers disease
  • Emerging novel diagnostic technologies
  • Increasing pipeline drugs

To know more about this report, request a free sample copy.

The important drivers increasing growth in the global Alzheimer’s disease therapeutics and diagnostics market are the growing geriatric population and the rise in the pervasiveness of Alzheimer’s disease. Alzheimer’s disease is the key reason for dementia among the old age population, which is a normal part of the general aging process. Therefore, the rising geriatric population globally acts as a key driver for the global Alzheimer’s disease therapeutics and diagnostics market. The high prevalence of Alzheimer’s disease globally acts as a key driver for the growth of the global Alzheimer’s disease therapeutics and diagnostics market and emphasizes the need to develop an effective Alzheimer’s disease treatment.

In 2019, around 67.43% of revenue share was captured by therapeutics in terms of Alzheimer’s disease therapeutics and diagnostics, and was also anticipated to be the fastest-growing therapeutics and diagnostics. Therapeutics is further segmented into drugs, disease stage, as well as generic and branded. Diagnostics is further segmented into magnetic resonance imaging, computed tomography, positron emission tomography, lumbar puncture test, electroencephalography, and other diagnostics. Some of the commonly available drugs include Galantamine, marketed under the brand name Razadyne, Donepezil, marketed under Aricept, Memantine, marketed under the name Namenda and others. Branded medicine is the original product that has been developed by a pharmaceutical company. Lumbar puncture test, also known as a spinal tap, is a minimally invasive medical procedure in which Cerebrospinal Fluid (CSF) is collected for diagnostic testing. Positron Emission Tomography (PET) uses a camera, a computer, and radioactive materials called radiotracers in a small amount to evaluate organ and tissue malfunctions in Alzheimer’s diagnosis. MRI is used to detect brain abnormalities related to Mild Cognitive Impairment (MCI) that may eventually develop Alzheimer’s disease. The other diagnostics market comprises Alzheimers diagnosis using a blood test, SPECT (Single Photon Emission Computed Tomography), and other Alzheimer’s diagnostic methods.

Failure of the late-stage drugs and stringent government regulations are the major factors hindering Alzheimer’s disease therapeutics and diagnostics market. The increasing number of disease-modifying drugs in early phases of trials suggests the higher focus of industry on developing blockbuster products, which can cure the disease, however, decreasing the proportion of disease-modifying therapies in higher phases suggests significantly high failure rates of trials, especially in case of disease-modifying drugs. As per the Alzheimer’s drug discovery foundation, pharmacologic treatment for Alzheimers is first tested in clinical trials registered with clinical trials government a national institute of health registry of publicly and privately funded clinical studies.

The global Alzheimer’s disease therapeutics and diagnostics market segments include therapeutics and diagnostics.

Therapeutics and Diagnostics are segmented into:

  • Therapeutics
    • Therapeutics by drugs
      • Marketed drugs
      • Pipeline drugs
    • Therapeutics by disease stage
      • Late-stage: severe ad
      • Early/middle stage: mild to moderate ad
      • Prodromal stage
    • Therapeutics by generic and branded
      • Branded
      • Generic
    • Diagnostics
      • Lumbar puncture test
      • Positron emission tomography
      • Electroencephalography
      • Magnetic resonance imaging
      • Computed tomography
      • Other diagnostics

Geographically, the global Alzheimer’s disease therapeutics and diagnostics market is segregated as:

  • North America: The United States & Canada
  • Europe: The United Kingdom, France, Germany, Italy, Belgium, Russia, Poland, and the Rest of Europe
  • Asia Pacific: South Korea, China, Japan, India, Indonesia, Thailand, Vietnam, Australia & New Zealand, and the Rest of Asia Pacific
  • Rest of World: Latin America, the Middle East & Africa

In terms of geography, North America dominated the market with a revenue share of approx. 39% in 2019. Alzheimer’s disease therapeutics and diagnostics market in North America expected to hold the largest market share by 2028. According to the recent Alzheimer’s Association study, a significant percentage of seniors receive regular cognitive assessments during routine health check-ups. The US Food and Drug Administration has approved four molecules for the treatment of Alzheimer’s disease, which include rivastigmine, galantamine, donepezil, and memantine.

On the other hand, the Asia Pacific market is anticipated to the fastest-growing region for Alzheimer’s disease therapeutics and diagnostics market. China ranks first in the world in terms of the number of people with dementia and accounts for 20% of the total dementia cases worldwide. According to the report published by the Alzheimer’s and Related Disorders Society of India. From a global perspective, India ranks second with the highest number of individuals who are suffering from dementia. According to the Japanese Alzheimer’s and Dementia resources, in Japan at present, there are more than 4.6 million people living with dementia. This number is thus expected to rise significantly as the population ages. As per Dementia Australia, approximately 447,115 Australians are living with dementia in 2019, and the almost 1.5 million Australians involved in their center for care.

The major market players of the global Alzheimer’s disease therapeutics and diagnostics market are:

  • GE Healthcare
  • Allergan PLC
  • Eli Lilly & Company
  • Johnson & Johnson
  • Novartis AG
  • Others

Key strategies adopted by some of the Alzheimer’s disease therapeutics and diagnostics companies:

In October 2019, GE Healthcare partnered with the Society of Radiography in Kenya to improve Radiography training. GE Healthcare is a global provider of medical technologies and services for the diagnosis and treatment of cancer, heart disease, neurological diseases, woman’s health, and other conditions. In March 2018, Novartis announced an additional strategic alliance with Science 37, a leader in decentralized clinical trial technology and design, to initiate up to 10 new clinical trials over the next three years.

Key findings of the global Alzheimer’s disease therapeutics and diagnostics market:

  • The therapeutics segment garners the largest market share.
  • There is an increasing demand for the detection of Alzheimer’s in the elderly population.
  • Computed tomography is majorly used in the diagnostics of Alzheimer’s disease.
  • There have been advancements in in-vitro diagnostic techniques.
  • There is an increase in the number of deaths resulting from Alzheimer’s disease.
  • There has been an increase in R&D investment in personalized medicines.

Table of Contents

  1. RESEARCH SCOPE & METHODOLOGY
    • STUDY OBJECTIVES
    • SCOPE OF STUDY
    • METHODOLOGY
    • ASSUMPTIONS & LIMITATIONS
  2. EXECUTIVE SUMMARIES
    • MARKET SIZE & ESTIMATES
    • MARKET OVERVIEW
  3. MARKET DYNAMICS
    • PARENT MARKET ANALYSIS: ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET
    • MARKET DEFINITION
    • KEY DRIVERS
      • GROWING GERIATRIC POPULATION
      • RISE IN THE PERVASIVENESS OF ALZHEIMER’S DISEASE
      • EMERGING NOVEL DIAGNOSTIC TECHNOLOGIES
      • INCREASING PIPELINE DRUGS
    • KEY RESTRAINTS
      • FAILURE OF THE LATE-STAGE DRUGS
      • STRINGENT GOVERNMENT REGULATIONS
      • HIGH COST OF THERAPIES USED FOR THE TREATMENT OF ALZHEIMER’S DISEASE
  1. KEY ANALYTICS
    • PORTER’S FIVE FORCE ANALYSIS
      • THREAT OF NEW ENTRY
      • THREAT OF SUBSTITUTION
      • BUYER’S POWER
      • SUPPLIER’S POWER
      • COMPETITIVE RIVALRY
    • KEY BUYING CRITERIA
      • PRICE
      • EFFICIENCY
      • SAFETY
    • ETYMOLOGY OF ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET
    • SUPPLY CHAIN ANALYSIS
      • RESEARCH AND DEVELOPMENT
      • RAW MATERIALS
      • MANUFACTURING
      • WHOLESALERS
      • END USER
    • PHASES AND STERNNESS OF ALZHEIMER’S DISEASE
    • OPPORTUNITY MATRIX
    • VENDOR LANDSCAPE
    • KEY INVESTMENT INSIGHTS
  2. MARKET BY THERAPEUTICS AND DIAGNOSTICS
    • THERAPEUTICS
      • THERAPEUTICS BY DRUGS
        • MARKETED DRUGS
        • PIPELINE DRUGS
      • THERAPEUTICS BY DISEASE STAGE
        • LATE STAGE: SEVERE AD
        • EARLY/MIDDLE STAGE: MILD TO MODERATE AD
        • PRODROMAL STAGE
      • THERAPEUTICS BY GENERIC AND BRANDED
        • BRANDED
        • GENERIC
    • DIAGNOSTICS
      • LUMBAR PUNCTURE TEST
      • POSITRON EMISSION TOMOGRAPHY
      • ELECTROENCEPHALOGRAPHY
      • MAGNETIC RESONANCE IMAGING
      • COMPUTED TOMOGRAPHY
      • OTHER DIAGNOSTICS
  1. GEOGRAPHICAL ANALYSIS
    • NORTH AMERICA
      • THE UNITED STATES
      • CANADA
    • EUROPE
      • THE UNITED KINGDOM
      • FRANCE
      • GERMANY
      • ITALY
      • RUSSIA
      • BELGIUM
      • POLAND
      • REST OF EUROPE
    • ASIA PACIFIC
      • CHINA
      • INDIA
      • JAPAN
      • AUSTRALIA & NEW ZEALAND
      • SOUTH KOREA
      • THAILAND
      • INDONESIA
      • VIETNAM
      • REST OF ASIA PACIFIC
    • REST OF WORLD
      • LATIN AMERICA
      • MIDDLE EAST & AFRICA
  1. COMPANY PROFILES
    • ALLERGAN PLC
    • AMARANTUS BIOSCIENCE HOLDINGS INC.
    • BAXTER INTERNATIONAL INC.
    • BIOGEN INC.
    • COGNOPTIX, INC.
    • EISAI CO. LTD
    • ELI LILLY & COMPANY
    • HOFFMANN-LA ROCHE
    • GE HEALTHCARE
    • JOHNSON & JOHNSON
    • LUPIN LIMITED
    • MERCK & CO. INC.
    • NOVARTIS AG
    • PFIZER INC.
    • SUN PHARMACEUTICALS INDUSTRIES LTD.

TABLE LIST

TABLE 1: MARKET SNAPSHOT – ALZHEIMER’S DISEASE AND THERAPEUTICS

TABLE 2: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS AND DIAGNOSTICS, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 3: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS AND DIAGNOSTICS, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 4: GLOBAL THERAPEUTICS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 5: GLOBAL THERAPEUTICS MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 6: GLOBAL THERAPEUTICS MARKET, BY DRUGS, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 7: GLOBAL THERAPEUTICS MARKET, BY DRUGS, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 8: GLOBAL MARKETED DRUGS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 9: GLOBAL MARKETED DRUGS MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 10: GLOBAL PIPELINE DRUGS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 11: GLOBAL PIPELINE DRUGS MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 12: GLOBAL THERAPEUTICS MARKET, BY DRUGS, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 13: GLOBAL THERAPEUTICS MARKET, BY DRUGS, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 14: GLOBAL LATE STAGE: SEVERE AD MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 15: GLOBAL LATE STAGE: SEVERE AD MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 16: GLOBAL EARLY/MIDDLE STAGE: MILD TO MODERATE AD MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 17: GLOBAL EARLY/MIDDLE STAGE: MILD TO MODERATE AD MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 18: GLOBAL PRODROMAL STAGE MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 19: GLOBAL PRODROMAL STAGE MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 20: GLOBAL THERAPEUTICS MARKET, BY DRUGS, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 21: GLOBAL THERAPEUTICS MARKET, BY DRUGS, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 22: GLOBAL BRANDED MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 23: GLOBAL BRANDED MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 24: GLOBAL GENERIC MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 25: GLOBAL GENERIC MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 26: GLOBAL DIAGNOSTICS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 27: GLOBAL DIAGNOSTICS MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 28: GLOBAL DIAGNOSTICS MARKET, BY TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 29: GLOBAL DIAGNOSTICS MARKET, BY TYPE, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 30: GLOBAL LUMBAR PUNCTURE TEST MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 31: GLOBAL LUMBAR PUNCTURE TEST MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 32: GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 33: GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 34: GLOBAL ELECTROENCEPHALOGRAPHY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 35: GLOBAL ELECTROENCEPHALOGRAPHY MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 36: GLOBAL MAGNETIC RESONANCE IMAGING MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 37: GLOBAL MAGNETIC RESONANCE IMAGING MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 38: GLOBAL COMPUTED TOMOGRAPHY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 39: GLOBAL COMPUTED TOMOGRAPHY MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 40: GLOBAL OTHER DIAGNOSTICS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 41: GLOBAL OTHER DIAGNOSTICS MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 42: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 43: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 44: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 45: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 46: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 47: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 48: ASIA PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 49: ASIA PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 50: REST OF WORLD ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 51: REST OF WORLD ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

FIGURE LIST          

FIGURE 1: PIPELINE DRUGS RELATED TO ALZHEIMER’S DISEASE

FIGURE 2: COSTS OF CARE FOR PEOPLE WITH ALZHEIMER’S AND OTHER DEMENTIAS, 2017 ($ BILLION)

FIGURE 3: PORTER’S FIVE FORCE ANALYSIS

FIGURE 4: SUPPLY CHAIN ANALYSIS

FIGURE 5: OPPORTUNITY MATRIX

FIGURE 6: VENDOR LANDSCAPE

FIGURE 7: KEY INVESTMENT INSIGHTS

FIGURE 8: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS, 2020-2028 ($ MILLION)

FIGURE 9: GLOBAL THERAPEUTICS MARKET, BY MARKETED DRUGS, 2020-2028 ($ MILLION)

FIGURE 10: GLOBAL THERAPEUTICS MARKET, BY PIPELINE DRUGS, 2020-2028 ($ MILLION)

FIGURE 11: GLOBAL THERAPEUTICS MARKET, BY LATE STAGE: SEVERE AD, 2020-2028 ($ MILLION)

FIGURE 12: GLOBAL THERAPEUTICS MARKET, BY EARLY/MIDDLE STAGE: MILD TO MODERATE AD, 2020-2028 ($ MILLION)

FIGURE 13: GLOBAL THERAPEUTICS MARKET, BY PRODROMAL STAGE, 2020-2028 ($ MILLION)

FIGURE 14: GLOBAL THERAPEUTICS MARKET, BY BRANDED, 2020-2028 ($ MILLION)

FIGURE 15: GLOBAL THERAPEUTICS MARKET, BY GENERIC, 2020-2028 ($ MILLION)

FIGURE 16: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2020-2028 ($ MILLION)

FIGURE 17: GLOBAL DIAGNOSTICS MARKET, BY LUMBAR PUNCTURE TEST, 2020-2028 ($ MILLION)

FIGURE 18: GLOBAL DIAGNOSTICS MARKET, BY POSITRON EMISSION TOMOGRAPHY, 2020-2028 ($ MILLION)

FIGURE 19: GLOBAL DIAGNOSTICS MARKET, BY ELECTROENCEPHALOGRAPHY, 2020-2028 ($ MILLION)

FIGURE 20: GLOBAL DIAGNOSTICS MARKET, BY MAGNETIC RESONANCE IMAGING, 2020-2028 ($ MILLION)

FIGURE 21: GLOBAL DIAGNOSTICS MARKET, BY COMPUTED TOMOGRAPHY, 2020-2028 ($ MILLION)

FIGURE 22: GLOBAL DIAGNOSTICS MARKET, BY OTHER DIAGNOSTICS, 2020-2028 ($ MILLION)

FIGURE 23: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)

FIGURE 24: THE UNITED STATES ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)

FIGURE 25: CANADA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)

FIGURE 26: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)

FIGURE 27: THE UNITED KINGDOM ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)

FIGURE 28: FRANCE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)

FIGURE 29: GERMANY ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)

FIGURE 30: ITALY ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)

FIGURE 31: RUSSIA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)

FIGURE 32: BELGIUM ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)

FIGURE 33: POLAND ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)

FIGURE 34: REST OF EUROPE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)

FIGURE 35: ASIA PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)

FIGURE 36: CHINA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)

FIGURE 37: INDIA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)

FIGURE 38: JAPAN ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)

FIGURE 39: AUSTRALIA & NEW ZEALAND ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)

FIGURE 40: SOUTH KOREA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)

FIGURE 41: THAILAND ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)

FIGURE 42: INDONESIA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)

FIGURE 43: VIETNAM ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)

FIGURE 44: REST OF ASIA PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)

FIGURE 45: REST OF WORLD ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)

FIGURE 46: LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)

FIGURE 47: MIDDLE EAST & AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)

Segmentation

  1. MARKET BY THERAPEUTICS AND DIAGNOSTICS
    • THERAPEUTICS
      • THERAPEUTICS BY DRUGS
        • MARKETED DRUGS
        • PIPELINE DRUGS
      • THERAPEUTICS BY DISEASE STAGE
        • LATE STAGE: SEVERE AD
        • EARLY/MIDDLE STAGE: MILD TO MODERATE AD
        • PRODROMAL STAGE
      • THERAPEUTICS BY GENERIC AND BRANDED
        • BRANDED
        • GENERIC
    • DIAGNOSTICS
      • LUMBAR PUNCTURE TEST
      • POSITRON EMISSION TOMOGRAPHY
      • ELECTROENCEPHALOGRAPHY
      • MAGNETIC RESONANCE IMAGING
      • COMPUTED TOMOGRAPHY
      • OTHER DIAGNOSTICS
  1. GEOGRAPHICAL ANALYSIS
    • NORTH AMERICA
      • THE UNITED STATES
      • CANADA
    • EUROPE
      • THE UNITED KINGDOM
      • FRANCE
      • GERMANY
      • ITALY
      • RUSSIA
      • BELGIUM
      • POLAND
      • REST OF EUROPE
    • ASIA PACIFIC
      • CHINA
      • INDIA
      • JAPAN
      • AUSTRALIA & NEW ZEALAND
      • SOUTH KOREA
      • THAILAND
      • INDONESIA
      • VIETNAM
      • REST OF ASIA PACIFIC
    • REST OF WORLD
      • LATIN AMERICA
      • MIDDLE EAST & AFRICA

Request Free Sample

To request a free sample copy of this report, please complete the form below :

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

Choose License Type

Buy Now

Inkwood Research